{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T18:01:41Z","timestamp":1787767301243,"version":"build-2784847793"},"reference-count":99,"publisher":"Informa UK Limited","issue":"sup1","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Biological Therapy"],"published-print":{"date-parts":[[2015,6,30]]},"DOI":"10.1517\/14712598.2015.1033393","type":"journal-article","created":{"date-parts":[[2015,6,22]],"date-time":"2015-06-22T08:39:30Z","timestamp":1434962370000},"page":"117-127","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":49,"title":["Historical review of thymosin \u03b1 1 in infectious diseases"],"prefix":"10.1517","volume":"15","author":[{"given":"Roberto","family":"Camerini","sequence":"first","affiliation":[{"name":"1Sigma-tau SpA, R&amp;D Department, Via Pontina km 30.400, 00040 Pomezia, Italy ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Garaci","sequence":"additional","affiliation":[{"name":"2Rector of S. Raffaele University, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2015,6,22]]},"reference":[{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(17)37900-0"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(17)37901-2"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.imlet.2007.04.007"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.embor.7400433"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-11-4036"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-02-004762"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1415.002"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2010.05465.x"},{"key":"e_1_3_2_11_1","first-page":"111","article-title":"Enhanced immune response and antitumor immunity with combinations of biological response modifiers","volume":"65","author":"Garaci E","year":"1989","unstructured":"Garaci E, Mastino A, Favalli C. Enhanced immune response and antitumor immunity with combinations of biological response modifiers. Bull N Y Acad Med 1989;65:111-19","journal-title":"Bull N Y Acad Med"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00199694"},{"key":"e_1_3_2_13_1","first-page":"41","article-title":"In vivo recovery of natural killer cell activity by the association of thymosin alpha 1 and cytokines during cocaine administration","volume":"22","author":"Di Francesco P","year":"1994","unstructured":"Di Francesco P, Pica F, Graziano R, et al. In vivo recovery of natural killer cell activity by the association of thymosin alpha 1 and cytokines during cocaine administration. Med Sci Res 1994;22:41-2","journal-title":"Med Sci Res"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00205574"},{"key":"e_1_3_2_15_1","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.4049\/jimmunol.139.7.2338","article-title":"Modulation of human natural killer cell cytotoxic activity, limphokine production, and interleukine-2 receptor expression by thymic hormones","volume":"139","author":"Serrate SA","year":"1987","unstructured":"Serrate SA, Schulof RS, Leondaridis L, et al. Modulation of human natural killer cell cytotoxic activity, limphokine production, and interleukine-2 receptor expression by thymic hormones. J Immunol 1987;139:2338-43","journal-title":"J Immunol"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910500327"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01771450"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910570516"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002620050562"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02592405"},{"key":"e_1_3_2_21_1","first-page":"3571","article-title":"High doses of thymosin alpha 1 enhance the anti-tumor efficacy of combination chemo-immunotherapy for murine B16 melanoma","volume":"18","author":"Pica F","year":"1998","unstructured":"Pica F, Fraschetti M, Matteucci C, et al. High doses of thymosin alpha 1 enhance the anti-tumor efficacy of combination chemo-immunotherapy for murine B16 melanoma. Anticancer Res 1998;18:3571-8","journal-title":"Anticancer Res"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2012.06716.x"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02256128"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellbi.2008.07.011"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2007.00960.x"},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.83.16.6107"},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/0192-0561(89)90133-1"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/0192-0561(90)90064-T"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/0162-3109(89)90045-3"},{"key":"e_1_3_2_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/1521-4141(200003)30:3<778::AID-IMMU778>3.0.CO;2-I"},{"key":"e_1_3_2_31_1","volume-title":"6th International Expert Forum of Immunotherapy and Gene Therapy","author":"Palamara A","year":"1998","unstructured":"Palamara A, Bue M, Savini P, et al. Thymosin alpha 1 inhibits Sendai virus replication: involvement of intracellular redox state. 6th International Expert Forum of Immunotherapy and Gene Therapy, Florence, Italy; 1998"},{"key":"e_1_3_2_32_1","first-page":"5214","article-title":"Thymosin alpha 1 down-regulates the growth of human non-small cell lung cancer cells in vitro and in vivo","volume":"53","author":"Moody TW","year":"1993","unstructured":"Moody TW, Fagarasan M, Zia F, et al. Thymosin alpha 1 down-regulates the growth of human non-small cell lung cancer cells in vitro and in vivo. Cancer Res 1993;53:5214-18","journal-title":"Cancer Res"},{"key":"e_1_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-012-9365-4"},{"key":"e_1_3_2_34_1","first-page":"133","article-title":"Thymosin alpha 1 \u2013 a peptide immune modulator with a broad range of clinical applications","volume":"3","author":"Tuthill CW","year":"2013","unstructured":"Tuthill CW, King RS. Thymosin alpha 1 \u2013 a peptide immune modulator with a broad range of clinical applications. Clin Exp Pharmacol 2013;3:133","journal-title":"Clin Exp Pharmacol"},{"key":"e_1_3_2_35_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2001.01135.x"},{"key":"e_1_3_2_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2007.10.014"},{"key":"e_1_3_2_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1726-4901(09)70137-6"},{"key":"e_1_3_2_38_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v12.i41.6715"},{"key":"e_1_3_2_39_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v7.i3.407"},{"key":"e_1_3_2_40_1","doi-asserted-by":"publisher","DOI":"10.1186\/1743-422X-6-63"},{"key":"e_1_3_2_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.1996.tb00094.x"},{"key":"e_1_3_2_42_1","first-page":"798","article-title":"Combination thymosin alpha 1 and interferon alpha 2b in the treatment of anti-HBe-positive chronic hepatitis B in Turkey","volume":"49","author":"Saruc M","year":"2002","unstructured":"Saruc M, Yucenar H, Kucukmetin N, et al. Combination thymosin alpha 1 and interferon alpha 2b in the treatment of anti-HBe-positive chronic hepatitis B in Turkey. Hepatogastroenterology 2002;49:798-802","journal-title":"Hepatogastroenterology"},{"key":"e_1_3_2_43_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.10401"},{"key":"e_1_3_2_44_1","first-page":"426A","article-title":"A comparative trial of thymosin alone and thymosin plus interferon alpha in the treatment of Chinese patients with chronic hepatitis B (CHB)","volume":"26","author":"Lu Z","year":"1997","unstructured":"Lu Z, Gao J, Yao G, et al. A comparative trial of thymosin alone and thymosin plus interferon alpha in the treatment of Chinese patients with chronic hepatitis B (CHB). Hepatology 1997;26:426A","journal-title":"Hepatology"},{"key":"e_1_3_2_45_1","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1177\/135965350601100206","article-title":"A randomized, placebo controlled trial of thymosin alpha 1 and lymphoblastoid interferon for HBeAg-positive chronic hepatitis B","volume":"11","author":"Lim SG","year":"2006","unstructured":"Lim SG, Wai CT, Lee YM, et al. A randomized, placebo controlled trial of thymosin alpha 1 and lymphoblastoid interferon for HBeAg-positive chronic hepatitis B. Antivir Ther 2006;11:245-53","journal-title":"Antivir Ther"},{"key":"e_1_3_2_46_1","first-page":"A339","article-title":"Six-months follow-up on a 26 week trial of thymosin alpha 1 plus famciclovir in the treatment of Chinese immune tolerant adult patients with chronic hepatitis B","volume":"116","author":"Lau G","year":"1999","unstructured":"Lau G, Yuen S, Kwok A, et al. Six-months follow-up on a 26 week trial of thymosin alpha 1 plus famciclovir in the treatment of Chinese immune tolerant adult patients with chronic hepatitis B. Gastroenterol 1999;116:A339","journal-title":"Gastroenterol"},{"key":"e_1_3_2_47_1","article-title":"Thymosin alpha and lamivudine combination therapy in pediatric patients with chronic hepatitis B infection unresponsive to previous treatments: a pilot study","volume":"49","author":"Suoglu OD","year":"2001","unstructured":"Suoglu OD, Elkabes B, Sokucu S, Saner G. Thymosin alpha and lamivudine combination therapy in pediatric patients with chronic hepatitis B infection unresponsive to previous treatments: a pilot study. Gut 2001;49","journal-title":"Gut"},{"key":"e_1_3_2_48_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2008.05387.x"},{"key":"e_1_3_2_49_1","first-page":"216A","article-title":"Treatment of chronic hepatitis B using thymosin alpha 1 and a combination of two nucleoside analogues, lamivudine and famciclovir","volume":"28","author":"Leung Y","year":"1998","unstructured":"Leung Y, So T. Treatment of chronic hepatitis B using thymosin alpha 1 and a combination of two nucleoside analogues, lamivudine and famciclovir. Hepatology 1998;28:216A","journal-title":"Hepatology"},{"key":"e_1_3_2_50_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.39.5.679"},{"key":"e_1_3_2_51_1","volume-title":"Fourth International Meeting on Hepatitis C Virus and Related Viruses","author":"Moscarella S","year":"1997","unstructured":"Moscarella S, Buzzelli G, Monti M, et al. Treatment with interferon alpha and thymosin alpha 1 of naive patients affected by chronic hepatitis C. Fourth International Meeting on Hepatitis C Virus and Related Viruses; Kyoto, Japan; 1997"},{"key":"e_1_3_2_52_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510270430"},{"key":"e_1_3_2_53_1","first-page":"379","volume-title":"Therapies for Viral Hepatitis","author":"Sherman K","year":"1998","unstructured":"Sherman K, Sherman S. Inteferon plus thymosin alpha 1 treatment of chronic hepatitis C infection: a meta-analysis. In: Schinazi R, Sommadossi J, Thomas H, editors. Therapies for Viral Hepatitis. International Medical Press; London, England: 1998. p. 379-83"},{"key":"e_1_3_2_54_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2011.01524.x"},{"key":"e_1_3_2_55_1","doi-asserted-by":"publisher","DOI":"10.1097\/00003246-200107000-00002"},{"key":"e_1_3_2_56_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra021333"},{"key":"e_1_3_2_57_1","doi-asserted-by":"publisher","DOI":"10.1186\/cc11932"},{"key":"e_1_3_2_58_1","first-page":"451","article-title":"Cooperative group of immunomodulatory therapy of sepsis, clinical trial with a new immunomodulatory strategy: treatment of severe sepsis with Ulinastatin and Maipuxin","volume":"87","author":"Lin HY","year":"2007","unstructured":"Lin HY. Cooperative group of immunomodulatory therapy of sepsis, clinical trial with a new immunomodulatory strategy: treatment of severe sepsis with Ulinastatin and Maipuxin. Zhonghua Yi Xue Za Zhi 2007;87:451-7","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"e_1_3_2_59_1","first-page":"153","article-title":"Effects of thymosin alpha 1 on cell immunity function in patient with septic shock","volume":"19","author":"Chen J","year":"2007","unstructured":"Chen J. Effects of thymosin alpha 1 on cell immunity function in patient with septic shock. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue 2007;19:153-5","journal-title":"Zhongguo Wei Zhong Bing Ji Jiu Yi Xue"},{"key":"e_1_3_2_60_1","first-page":"206","article-title":"Influence of thymosin alpha 1 on the cellular immune function in patients with severe sepsis","volume":"27","author":"Zaho MY","year":"2007","unstructured":"Zaho MY, Cao Y, Fei D, et al. Influence of thymosin alpha 1 on the cellular immune function in patients with severe sepsis. Chin J Crit Care Med 2007;27:206-8","journal-title":"Chin J Crit Care Med"},{"key":"e_1_3_2_61_1","first-page":"139","article-title":"Effect of continuous blood purification and thymosin alpha1 on the cellular immunity in patient with severe sepsis: a prospective, randomized, controlled clinical trial","volume":"21","author":"Li YN","year":"2009","unstructured":"Li YN, Zhou LX, Qiang XH, et al. Effect of continuous blood purification and thymosin alpha1 on the cellular immunity in patient with severe sepsis: a prospective, randomized, controlled clinical trial. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue 2009;21:139-42","journal-title":"Zhongguo Wei Zhong Bing Ji Jiu Yi Xue"},{"key":"e_1_3_2_62_1","doi-asserted-by":"publisher","DOI":"10.1086\/590500"},{"key":"e_1_3_2_63_1","doi-asserted-by":"publisher","DOI":"10.1177\/0885066608326970"},{"key":"e_1_3_2_64_1","first-page":"883","article-title":"Treatment of patients with severe sepsis using ulinastatin and thymosin alpha 1: a prospective, randomized, controlled pilot study","volume":"122","author":"Chen H","year":"2009","unstructured":"Chen H, He MY, Li YM. Treatment of patients with severe sepsis using ulinastatin and thymosin alpha 1: a prospective, randomized, controlled pilot study. Chin Med J 2009;122:883-8","journal-title":"Chin Med J"},{"key":"e_1_3_2_65_1","first-page":"344","article-title":"Immunotherapy improves immune homeostasis and increases survival rate of septic patients","volume":"12","author":"Huang SW","year":"2009","unstructured":"Huang SW, Chen J, Ouyang B, et al. Immunotherapy improves immune homeostasis and increases survival rate of septic patients. Chin J Traumatol 2009;12:344-9","journal-title":"Chin J Traumatol"},{"key":"e_1_3_2_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2014.12.032"},{"key":"e_1_3_2_67_1","volume-title":"Oral presentation, 53rd ASH meeting","author":"Perrucio K","year":"2011","unstructured":"Perrucio K, Ruggeri L, Moretti S, et al. Thymosin Alfa 1 administration improves immune reconstitution and decreases infection-related mortality after HLA-matched sibling T cell-depleted stem cell transplantation [abstract n. 1013]. Oral presentation, 53rd ASH meeting, San Diego, USA; 2011"},{"key":"e_1_3_2_68_1","first-page":"637","article-title":"Effect of the thymosin alpha 1 on immune function in aged chronic obstructive pulmonary disease during acute period","volume":"27","author":"Li C","year":"2007","unstructured":"Li C, Wang C-H, Meng Q-H, et al. Effect of the thymosin alpha 1 on immune function in aged chronic obstructive pulmonary disease during acute period. Chin Hosp Pharm J 2007;27:637-9","journal-title":"Chin Hosp Pharm J"},{"key":"e_1_3_2_69_1","first-page":"588","article-title":"The prophylactic effect of thymsin alpha 1 on the acute exacerbation of chronic obstructive pulmonary disease","volume":"39","author":"Zheng BX","year":"2008","unstructured":"Zheng BX, Cheng BY, Xu G, et al. The prophylactic effect of thymsin alpha 1 on the acute exacerbation of chronic obstructive pulmonary disease. Sichuan Da Xue Xue Bao Yi Xue Ban 2008;39:588-90","journal-title":"Sichuan Da Xue Xue Bao Yi Xue Ban"},{"key":"e_1_3_2_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60604-7"},{"key":"e_1_3_2_71_1","first-page":"128","article-title":"Prevention and management of lung infections with thymosin alpha 1 in critical patients with tracheotomy","volume":"26","author":"Huang DP","year":"2006","unstructured":"Huang DP, Yang M, Peng WP, et al. Prevention and management of lung infections with thymosin alpha 1 in critical patients with tracheotomy. Nan Fang Yi Ke Da Xue Xue Bao 2006;26:128-9","journal-title":"Nan Fang Yi Ke Da Xue Xue Bao"},{"key":"e_1_3_2_72_1","first-page":"1271","article-title":"Treatment of drug-resistant Pseudomonas aeruginosa pneumonia in elderly patients by using thymosin alpha 1 with sulperazone","volume":"17","author":"Li P","year":"2007","unstructured":"Li P, Xu L-H, Zhang Q, et al. Treatment of drug-resistant Pseudomonas aeruginosa pneumonia in elderly patients by using thymosin alpha 1 with sulperazone. Chin J Nosocomial 2007;17:1271-3","journal-title":"Chin J Nosocomial"},{"key":"e_1_3_2_73_1","first-page":"332","article-title":"Clinical investigation of outbreak of nosocomial severe acute respiratory syndrome","volume":"15","author":"Gao ZC","year":"2003","unstructured":"Gao ZC, Zhu JH, Sun Y, et al. Clinical investigation of outbreak of nosocomial severe acute respiratory syndrome. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue 2003;15:332-5","journal-title":"Zhongguo Wei Zhong Bing Ji Jiu Yi Xue"},{"key":"e_1_3_2_74_1","first-page":"58","article-title":"Experience of successful recovery of one case of an elderly severe SARS patient","volume":"16","author":"Han Y","year":"2004","unstructured":"Han Y, Zhang X, Ji W, et al. Experience of successful recovery of one case of an elderly severe SARS patient. Chin Crit Care Med 2004;16:58","journal-title":"Chin Crit Care Med"},{"key":"e_1_3_2_75_1","first-page":"1901","article-title":"Imaging follow up of SARS patients complicated with pulmonary fibrosis","volume":"20","author":"Lu P","year":"2004","unstructured":"Lu P, Yang G, Yu W, et al. Imaging follow up of SARS patients complicated with pulmonary fibrosis. Chin J Med Imaging Technol 2004;20:1901-3","journal-title":"Chin J Med Imaging Technol"},{"key":"e_1_3_2_76_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00201961"},{"key":"e_1_3_2_77_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.48.2.234"},{"key":"e_1_3_2_78_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0065-2776(08)60901-3"},{"key":"e_1_3_2_79_1","first-page":"31","article-title":"The effect of thymosin alpha 1 on immunity to influenza in aged mice","volume":"1","author":"Effros RB","year":"1988","unstructured":"Effros RB, Casillas A, Walford RL. The effect of thymosin alpha 1 on immunity to influenza in aged mice. Aging 1988;1:31-40","journal-title":"Aging"},{"key":"e_1_3_2_80_1","doi-asserted-by":"publisher","DOI":"10.1016\/0162-3109(84)90045-6"},{"key":"e_1_3_2_81_1","volume-title":"Paper presented at Second Tissue Homotransplantation Conference","author":"Dammin G","year":"1957","unstructured":"Dammin G, Couch N, Murray J. Prolonged survival of skin homografts in uremic patients. Paper presented at Second Tissue Homotransplantation Conference; New York. 1957"},{"key":"e_1_3_2_82_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-62-1-166"},{"key":"e_1_3_2_83_1","first-page":"150","article-title":"T-cell subset and status of hepatitis B surface antigen and antibody in end-stage renal disease patients","volume":"27","author":"Revie D","year":"1985","unstructured":"Revie D, Shen S, Ordonez J, et al. T-cell subset and status of hepatitis B surface antigen and antibody in end-stage renal disease patients. Kidney Int 1985;27:150","journal-title":"Kidney Int"},{"key":"e_1_3_2_84_1","first-page":"768","article-title":"Suppression of interferon response in lymphocytes from patients with uremia","volume":"77","author":"Sanders CV","year":"1971","unstructured":"Sanders CVJr, Luby JP, Sanford JP, Hull AR. Suppression of interferon response in lymphocytes from patients with uremia. J Lab Clin Med 1971;77:768-76","journal-title":"J Lab Clin Med"},{"key":"e_1_3_2_85_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198408233110803"},{"key":"e_1_3_2_86_1","doi-asserted-by":"publisher","DOI":"10.1016\/0166-3542(83)90013-X"},{"key":"e_1_3_2_87_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(81)91847-X"},{"key":"e_1_3_2_88_1","unstructured":"Liu C Patel A Zhu H et al. In vitro studies to identify host genes or pathways involved in immune-mediated response to thymosin alpha 1 and peginterferon. 2002"},{"key":"e_1_3_2_89_1","volume-title":"American Association for the Study of Liver Disease","author":"Gramenzi A","year":"2005","unstructured":"Gramenzi A. In vitro effect of thymosin alpha 1 and interferon alpha on Th1 and Th2 cytokine synthesis in patients with HBEAg-negative chronic hepatitis B. American Association for the Study of Liver Disease, San Francisco, USA; 2005"},{"issue":"4","key":"e_1_3_2_90_1","first-page":"361A","article-title":"Thymosin alpha 1 plus interferon alpha enhance the immune and antiviral response of patients with hepatitis C virus infection","volume":"28","author":"Cursaro C","year":"1998","unstructured":"Cursaro C, Margotti M, Favarelli L, et al. Thymosin alpha 1 plus interferon alpha enhance the immune and antiviral response of patients with hepatitis C virus infection. Hepatology 1998;28(4):361A","journal-title":"Hepatology"},{"key":"e_1_3_2_91_1","doi-asserted-by":"publisher","DOI":"10.1016\/0192-0561(85)90065-7"},{"key":"e_1_3_2_92_1","doi-asserted-by":"publisher","DOI":"10.1016\/0192-0561(92)90098-6"},{"key":"e_1_3_2_93_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00916574"},{"key":"e_1_3_2_94_1","doi-asserted-by":"publisher","DOI":"10.1093\/geront\/26.2.150"},{"key":"e_1_3_2_95_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.1989.tb01561.x"},{"key":"e_1_3_2_96_1","first-page":"188A","article-title":"Augmentation of influenza antibody levels and reduction in attack rates in elderly subjects by thymosin alpha 1","volume":"29","author":"McConnell L","year":"1989","unstructured":"McConnell L, Gravenstein S, Roecker E, et al. Augmentation of influenza antibody levels and reduction in attack rates in elderly subjects by thymosin alpha 1. Gerontologist 1989;29:188A","journal-title":"Gerontologist"},{"key":"e_1_3_2_97_1","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/978-1-4613-0513-2_52","volume-title":"Biomedical advances in aging","author":"Shen SY","year":"1990","unstructured":"Shen SY, Corteza QB, Josselson J, et al. Age-dependent enhancement of influenza vaccine responses by thymosin in chronic hemodialysis patients. In: Goldstein AL, editor. Biomedical advances in aging. Plenum Press; New York, NY: 1990. p. 523-30"},{"key":"e_1_3_2_98_1","article-title":"Effect of thymosin alpha 1 on heptavax-B vaccination among hemodialysis patients","volume":"217","author":"Shen S","year":"1987","unstructured":"Shen S, Josselson J, McRoy C, et al. Effect of thymosin alpha 1 on heptavax-B vaccination among hemodialysis patients. Kidney Int 1987;217","journal-title":"Kidney Int"},{"key":"e_1_3_2_99_1","first-page":"1120","article-title":"Effects of thymosin alpha 1 on peripheral T-cell and heptavax-B vaccination in previously non-responsive hemodialysis patients","volume":"7","author":"Shen S","year":"1987","unstructured":"Shen S, Josselson J, McRoy C, et al. Effects of thymosin alpha 1 on peripheral T-cell and heptavax-B vaccination in previously non-responsive hemodialysis patients. Hepatology 1987;7:1120","journal-title":"Hepatology"},{"key":"e_1_3_2_100_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.12.014"},{"key":"e_1_3_2_101_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.5208"}],"container-title":["Expert Opinion on Biological Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1517\/14712598.2015.1033393","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T06:34:13Z","timestamp":1765953253000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1517\/14712598.2015.1033393"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,22]]},"references-count":99,"journal-issue":{"issue":"sup1","published-print":{"date-parts":[[2015,6,30]]}},"alternative-id":["10.1517\/14712598.2015.1033393"],"URL":"https:\/\/doi.org\/10.1517\/14712598.2015.1033393","relation":{},"ISSN":["1471-2598","1744-7682"],"issn-type":[{"value":"1471-2598","type":"print"},{"value":"1744-7682","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,22]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2015-06-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}